Polyclinique De Limoges — Clinical Trial Site

40 Registered trials

15 Currently recruiting

Organisation

Polyclinique De Limoges

Location

Limoges Cedex I, France

Identifier

ORG-100044277

Address

18 Rue Du General Catroux, 87039, France

Departments

#40022: Rheumatology
Cabinet d’Algologie – Polyclinique Chenieux
Centre satellite Clinique Emailleurs - Colombier
Department of Medical Oncology
Department of Oncology
François Chénieux
Médecine Générale -Douleur
Medical Oncology
N/A
Oncologie
Oncologie médicale
Oncologie Radiothérapie
oncology
Oncology-Radiotherapy
Radiotherapy
Radiotherapy Oncology
Rhumatologie
Service d'Oncologie Médicale
Service oncologie radiothérapie
Urology

Clinical trials at this site (40)

Search interface

Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has… Ended

2024-514644-93-00 Metastatic renal cell carcinoma (mRCC) with a good or o 5 2022-12-09
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Clear cell renal cancer 5 2021-05-11
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Advanced RCC with clear cell component 5 2021-04-19
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Only patients with oncologic locally advanced or metast 5 2022-01-14
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended

2024-514934-19-00 Post-surgical neuropathic pain 5 2021-11-08
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29